D2 GASTRECTOMY VS D1:
WHY SURGICAL TECHNIQUE MATTERS IN GASTRIC CANCER
The extent of lymph node dissection during gastrectomy is one of the most important surgical decisions in gastric cancer โ D2 is the global standard, but is still not universally performed outside East Asia.
analyticsAt a Glance
- check_circleD2 lymphadenectomy is the globally accepted standard for curative-intent gastric cancer surgery
- check_circleDutch Trial 15-year data: D2 reduces local recurrence and improves gastric cancer-specific survival
- check_circleD2 should be performed without routine splenectomy or pancreatectomy (modified D2)
- check_circleChina, Japan, and Korea achieve the highest D2 volumes globally โ with world-leading outcomes
What D1, D2, and D3 Actually Mean
The "D" designation in gastric cancer surgery refers to the extent of lymph node dissection โ not the type of gastric resection. It describes which numbered lymph node stations are removed along with the stomach.
D1 Lymphadenectomy
Removal of the perigastric lymph nodes immediately adjacent to the stomach โ nodes in the lesser and greater omentum (stations 1โ6). D1 is the minimum acceptable nodal dissection. It provides limited staging information and leaves behind potentially involved second-tier nodes along the major gastric feeding vessels.
D2 Lymphadenectomy
D1 nodes + second-tier nodes along the left gastric artery (station 7), common hepatic artery (station 8), celiac axis (station 9), splenic hilum (station 10 โ for proximal tumours), and splenic artery (station 11). D2 is the global standard for potentially curative gastric cancer surgery.
Trial Evidence for D2 vs D1: What the Data Shows
Long-term data from randomised trials and East Asian registries have definitively established D2 as the superior approach for curative gastric cancer surgery.
| Trial / Data Source | Key Finding | Implication |
|---|---|---|
| Dutch Gastric Cancer Trial (15-year follow-up) | D2 vs D1: significantly lower local recurrence (12% vs 22%); improved gastric cancer-specific survival; no difference in 5-yr OS (confounded by early D2 complication excess from splenectomy/pancreatectomy) | D2 without splenopancreatectomy is safer and oncologically superior โ now the global standard |
| Dutch Trial: modified D2 subgroup | When analysis excludes pancreas/spleen resections, D2 morbidity and mortality approach D1 levels | Modified D2 (no routine splenectomy or distal pancreatectomy) eliminates excess morbidity seen in early Western D2 series |
| Japanese JCOG0703 / Korean KLASS data | D2 at high-volume Asian centres: 30-day mortality <1%; morbidity 10โ15%; 5-yr OS for Stage II/III: 55โ70% | Volume and training matter โ D2 complication rates at Asian expert centres are comparable to D1 in Western series |
| Italian D1+ trial | D1+ (D1 + stations 7, 8, 9 nodes) non-inferior to D2 for 5-yr OS at Italian centres with limited D2 training | D1+ is an acceptable compromise when D2 expertise is unavailable โ but not preferred over D2 at trained centres |
| Minimum lymph node count standard | UICC/AJCC: minimum 15 lymph nodes required for accurate N staging in gastric cancer | D1 frequently yields <15 nodes โ leading to understaging and inappropriate de-escalation of adjuvant therapy |
Total vs Subtotal Gastrectomy: The Other Key Technical Decision
Beyond lymph node extent, the amount of stomach removed โ total vs subtotal gastrectomy โ directly affects nutritional outcomes and quality of life after surgery.
Subtotal Gastrectomy
Removal of approximately 75โ80% of the stomach, preserving the proximal remnant. Appropriate for distal gastric cancers (antrum/pylorus) with โฅ5 cm proximal clear margin. Preferred over total gastrectomy where oncologically safe โ maintains better nutritional status and quality of life (less dumping, fewer nutritional deficiencies).
Total Gastrectomy
Removal of the entire stomach with Roux-en-Y oesophagojejunostomy reconstruction. Required for proximal (cardia/fundus) and mid-body gastric cancers, diffuse-type gastric cancer, or any tumour where subtotal resection cannot achieve adequate margins. Requires lifelong nutritional supplementation (B12, iron, fat-soluble vitamins) and dietary adaptation.
D2 Gastrectomy in East Asia vs Western Centres
The gap between East Asian and Western gastric cancer outcomes is partially explained by the universal adoption of D2 lymphadenectomy at high-volume Asian centres โ where D2 is performed with low morbidity and exceptional staging accuracy.
East Asian Practice (Japan, Korea, China)
- D2 is universal standard โ all curative casesOver 90% of curative gastric resections at Japanese, Korean, and Chinese academic centres include D2 lymphadenectomy as a minimum
- High individual surgeon volumeJapanese and Korean high-volume surgeons perform 50โ200 gastrectomies annually โ experience directly reduces D2 complication rates
- Laparoscopic D2 now standard for early gastric cancerJCOG0912 and KLASS-01 established laparoscopic D2 gastrectomy as safe and oncologically equivalent to open for cT1โT2 N0 gastric cancer
- Specialised gastric cancer multidisciplinary teamsDedicated gastric cancer tumour boards, neoadjuvant chemotherapy protocols (FLOT, SOX, XELOX), and standardised pathological assessment
Western Practice Considerations
- D2 not universally performed at non-specialist Western centresMany general surgeons in Western countries default to D1 or D1+ โ leaving second-tier nodes undissected
- Lower individual surgeon volumeLower gastric cancer incidence in Western populations means fewer surgeons achieve the volume needed for low-complication D2
- International patients can access East Asian expertisePatients in regions with limited gastric cancer surgical expertise can access world-leading D2 centres in China, Japan, and India through CancerFax
D2 Gastrectomy: Outcome Benchmarks
- <1%30-Day Mortality โ D2 at High-Volume Asian Centresvs 4โ10% in early Western D2 series โ experience eliminates the early excess mortality
- 22% โ 12%Local Recurrence Reduction โ D2 vs D1 (Dutch 15-yr)D2 halves local recurrence at 15 years in the definitive randomised trial
- โฅ15Minimum Lymph Nodes for Accurate StagingUICC requirement โ D1 frequently fails to meet this threshold
- 55โ70%5-Year OS โ Stage II/III After D2 + Adjuvant (Asia)Japanese/Korean series with D2 + S-1 or XELOX adjuvant chemotherapy
Related Cancer Surgery Resources
Explore more surgical oncology guides relevant to gastric cancer patients.
Frequently Asked Questions
D2 Gastrectomy for Gastric Cancer
How do I know if my surgeon is planning a D2 lymphadenectomy?
Ask directly: "Will you be performing a D2 lymphadenectomy?" and "How many lymph nodes do you typically remove in your gastric cancer resections?" A surgeon performing proper D2 should routinely yield โฅ25โ30 lymph nodes in the specimen. If you receive an answer below 15 nodes, D2 was almost certainly not performed. At academic cancer centres in Japan, Korea, China, and India, D2 is the automatic standard โ you are unlikely to receive D1 at a high-volume gastric cancer centre in East Asia. CancerFax can coordinate a second surgical opinion if you are uncertain about your proposed operative plan.
Does D2 cause more complications than D1?
At experienced high-volume centres, modified D2 (without routine splenectomy or distal pancreatectomy) has complication rates comparable to D1. The early Dutch Trial showed higher D2 morbidity because many surgeons included unnecessary spleen and pancreatic tail resections. Long-term data and more recent Asian series demonstrate that D2 without splenopancreatectomy achieves low morbidity (<15% overall), <1% mortality, and superior oncological outcomes. The key is surgeon volume and training โ not the procedure itself.
Should I travel to Japan, Korea, China, or India for gastric cancer surgery?
For patients in countries where gastric cancer surgical expertise is limited or where D2 gastrectomy is not routinely practised, accessing care at a high-volume gastric cancer centre in East Asia is a clinically sound decision. China and India in particular offer world-class gastric surgical oncology at costs significantly lower than Japan, Korea, or Western countries. CancerFax can identify the appropriate centre based on your staging and health status, coordinate a pre-operative second opinion, and manage the logistics of international surgical access.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Facing Gastric Cancer Surgery? Get an Expert Second Opinion.
Upload your CT staging, biopsy, and endoscopy reports. CancerFax will assess your D2 eligibility and identify specialist gastric surgeons at high-volume centres in India or China.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.